Business Description
Gongwin Biopharm Holdings Co Ltd
ISIN : KYG409471060
Total Employee Number:
27Description
Gongwin Biopharm Holdings Co Ltd is a Taiwan-based biopharmaceutical company focused on developing novel anti-cancer drugs. The company develops products related to central lung serious tracheal obstruction, primary liver cancer, malignant pleural effusion, and tracheal adenoid cystic carcinoma. The Group includes pharmaceutical research and development, drug testing, pharmaceutical technology consulting, biotechnology services, technology transfer, and the sale of new drugs.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 14.06 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -1.25 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 27.24 | |||||
Beneish M-Score | -2.8 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 209 | |||||
3-Year EBITDA Growth Rate | 30.2 | |||||
3-Year EPS without NRI Growth Rate | 25.9 | |||||
3-Year FCF Growth Rate | 19.5 | |||||
3-Year Book Growth Rate | 18.8 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.61 | |||||
9-Day RSI | 52.53 | |||||
14-Day RSI | 57.47 | |||||
3-1 Month Momentum % | 6.46 | |||||
6-1 Month Momentum % | -15.08 | |||||
12-1 Month Momentum % | -40.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.36 | |||||
Quick Ratio | 10.35 | |||||
Cash Ratio | 10.11 | |||||
Days Inventory | 91.58 | |||||
Days Sales Outstanding | 131.51 | |||||
Days Payable | 6.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.7 | |||||
Shareholder Yield % | 3.19 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 71.58 | |||||
Operating Margin % | -573.27 | |||||
Net Margin % | -313.14 | |||||
EBITDA Margin % | -285.32 | |||||
FCF Margin % | -379.22 | |||||
OCF Margin % | -372.48 | |||||
ROE % | -4.2 | |||||
ROA % | -3.84 | |||||
ROIC % | -20.08 | |||||
3-Year ROIIC % | 8.29 | |||||
ROC (Joel Greenblatt) % | -35.61 | |||||
ROCE % | -4.13 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 337.84 | |||||
PB Ratio | 4.84 | |||||
Price-to-Tangible-Book | 4.85 | |||||
EV-to-EBIT | -89.92 | |||||
EV-to-EBITDA | -100.06 | |||||
EV-to-Revenue | 285.49 | |||||
EV-to-FCF | -80.1 | |||||
Price-to-GF-Value | 0.66 | |||||
Price-to-Projected-FCF | 10.25 | |||||
| Price-to-Net-Current-Asset-Value | 7.65 | |||||
| Price-to-Net-Cash | 7.87 | |||||
Earnings Yield (Greenblatt) % | -1.12 | |||||
FCF Yield % | -1.14 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gongwin Biopharm Holdings Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 36.446 | ||
| EPS (TTM) (NT$) | -0.927 | ||
| Beta | -0.0072 | ||
| 3-Year Sharpe Ratio | -1.17 | ||
| 3-Year Sortino Ratio | -1.3 | ||
| Volatility % | 36.87 | ||
| 14-Day RSI | 57.47 | ||
| 14-Day ATR (NT$) | 7.038268 | ||
| 20-Day SMA (NT$) | 91.91 | ||
| 12-1 Month Momentum % | -40.18 | ||
| 52-Week Range (NT$) | 58.3 - 120 | ||
| Shares Outstanding (Mil) | 121.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gongwin Biopharm Holdings Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gongwin Biopharm Holdings Co Ltd Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Gongwin Biopharm Holdings Co Ltd Frequently Asked Questions
What is Gongwin Biopharm Holdings Co Ltd(ROCO:6617)'s stock price today?
The current price of ROCO:6617 is NT$100.00. The 52 week high of ROCO:6617 is NT$120.00 and 52 week low is NT$58.30.
When is next earnings date of Gongwin Biopharm Holdings Co Ltd(ROCO:6617)?
The next earnings date of Gongwin Biopharm Holdings Co Ltd(ROCO:6617) is .
Does Gongwin Biopharm Holdings Co Ltd(ROCO:6617) pay dividends? If so, how much?
Gongwin Biopharm Holdings Co Ltd(ROCO:6617) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Gongwin Biopharm Holdings Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers